Drug Profile
AZD 8835
Alternative Names: AZD-8835Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antineoplastics; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Solid tumours
Most Recent Events
- 02 May 2016 Discontinued - Phase-I for Breast cancer (Combination therapy, Late-stage disease) in United Kingdom (PO) (AstraZeneca pipeline, May 2016)
- 02 May 2016 Discontinued - Phase-I for Breast cancer (Combination therapy, Late-stage disease) in USA (PO) (AstraZeneca pipeline, May 2016)
- 02 May 2016 Discontinued - Phase-I for Solid tumours (Late-stage disease, Monotherapy) in United Kingdom (PO) (AstraZeneca pipeline, May 2016)